Skip to main content

Table 4 Response rate, objective response rate, and disease control rate

From: Safety and effectiveness of eribulin in Japanese patients with soft tissue sarcoma including rare subtypes: a post-marketing observational study

  

Response rate, n

ORR (CR + PR)

DCR

Soft tissue sarcoma subtypea

n

CR

PR

SD

SD

(≥11 W)

PD

NE

(%)

(%)

All

235

1

18

81

47

129

6

8.1

42.6

L-type

135

1

7

60

37

64

3

5.9

50.4

Non-L-type

100

0

11

21

10

65

3

11.0

32.0

Leiomyosarcoma

71

1

4

30

14

36

0

7.0

49.3

Liposarcoma

64

0

3

30

23

28

3

4.7

51.6

 Dedifferentiated

37

0

0

19

15

17

1

0.0

51.4

 Myxoid

12

0

3

4

2

3

2

25.0

58.3

 Well-differentiated

6

0

0

4

4

2

0

0.0

66.7

 Pleomorphic

3

0

0

0

0

3

0

0.0

0.0

 Unknown

6

0

0

3

2

3

0

0.0

50.0

Undifferentiated pleomorphic sarcoma

18

0

2

2

1

14

0

11.1

22.2

Angiosarcoma

13

0

2

2

2

9

0

15.4

30.8

Synovial sarcoma

13

0

3

3

1

7

0

23.1

46.2

Rhabdomyosarcoma

11

0

2

0

0

8

1

18.2

18.2

Malignant peripheral nerve sheath tumor

5

0

0

0

0

5

0

0.0

0.0

Myxofibrosarcoma

5

0

1

1

0

2

1

20.0

40.0

  1. CR complete response rate, DCR disease control rate, NE not evaluable, ORR objective response rate, PD progressive disease, PR partial response, SD stable disease, W weeks
  2. aLimited to subtypes with 5 or more patients